Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes
Open Access
Abstract
Background: Cardiovascular disease (CVD) is a leading cause of mortality in Type 2 diabetes mellitus (T2DM). Sodium-glucose co-transporter 2 (SGLT2) inhibitors are known to provide cardioprotective effects, but their influence on validated cardiovascular risk models remains underexplored. This study assessed the impact of SGLT2 inhibitors on cardiovascular risk scores, metabolic parameters, and laboratory profiles over six months. Methods: This study was conducted on 152 T2DM patients initiating SGLT2 inhibitors. Cardiovascular risk was evaluated using the SCORE2-DM model at baseline and after six months. Generalized Estimating Equation (GEE) analysis assessed temporal risk stratification changes. Metabolic parameters and laboratory profiles were analyzed using repeated-measures ANOVA. Results: Cardiovascular risk scores decreased significantly, i.e., from 21.68 to 17.43 (p < 0.001). Systolic and diastolic blood pressure were reduced by 9.21 mmHg and 6.16 mmHg, respectively (p < 0.001). BMI declined by 1.27 kg/m2 (p < 0.001), and HbA1c decreased by 1.38% (p < 0.001). Triglyceride levels dropped by 22.91 mg/dL (p < 0.001), while renal parameters remained stable. The GEE analysis confirmed significant shifts to lower cardiovascular risk categories (β = −0.777, p < 0.001), with comparable efficacy between empagliflozin and dapagliflozin (p = 0.922). Conclusions: SGLT2 inhibitor therapy significantly reduces cardiovascular risk and improves metabolic and laboratory parameters in T2DM patients. These findings highlight the importance of integrating SGLT2 inhibitors into comprehensive cardiometabolic management strategies.Keywords
This publication has 88 references indexed in Scilit:
- The Burden of Diabetes in the Southeastern Coastal Region of China From 1990 to 2019 and Projections for 2030: A Systematic Analysis of the 2019 Global Burden of Disease StudyDiabetes/Metabolism Research and Reviews, 2025
- Stem cells vesicles-loaded type I pro-photosensitizer for synergetic oxygen-independent phototheranostics and microenvironment regulation in infected diabetic woundsChemical Engineering Journal, 2025
- Screening for primary aldosteronism on and off interfering medicationsEndocrine, 2023
- SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug typeAtherosclerosis, 2023
- Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME ResultsCanadian Journal of Cardiology, 2020
- Use of Sodium–Glucose Co-Transporter-2 Inhibitors in Patients with and without Type 2 Diabetes: Implications for Incident and Prevalent Heart FailureEuropean Journal of Heart Failure, 2020
- The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta‐AnalysisObesity, 2017
- Model‐Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With CanagliflozinThe Journal of Clinical Pharmacology, 2017
- Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery diseaseHeart Failure Reviews, 2017
- Impact of Atrial Fibrillation on Outcomes in Patients Who Underwent Transcatheter Aortic Valve ReplacementThe American Journal of Cardiology, 2015